Clinical Trial Update: Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating systemic sirolimus (rapamycin) to prevent in-stent restenosis after pulmonary artery stent placement in peripheral pulmonary stenosis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• In-stent Restenosis
• Peripheral Pulmonary Stenosis

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: Boston Children's Hospital | Conditions: Peripheral Pulmonary Stenosis, In-stent Stenosis | Phase 2 | Status: WITHDRAWN